2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Sarcoma
6
Pancreatic Neoplasms
6
Neoplasm Metastasis
6
Colorectal Neoplasms
5
Sarcoma, Ewing
4
Ovarian Neoplasms
4
Breast Neoplasms
4
Neoplasms
3
Insulin-Like Growth Factor I, Resistance To
3
Carcinoma, Non-Small-Cell Lung
3
Rectal Neoplasms
2
Lymphoma
2
Colonic Neoplasms
2
Carcinoid Tumor
2
Adenocarcinoma
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pleural Effusion, Malignant
1
Pathologic Complete Response
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroectodermal Tumors, Primitive
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
Stents
2
Cholangiopancreatography, Endoscopic Retrograde
2
ganitumab
1
Surgical Procedures, Operative
1
Gemcitabine
1
Endoscopic Ultrasound-Guided Fine Needle Aspiration
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Jaundice
×
ganitumab
×
Clear all
NCT01231347
2024-07-16
GAMMA
NantCell, Inc.
Phase 3
Completed
800 enrolled
11 charts